# Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

> **NCT04910295** · — · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 112 (actual)

## Conditions studied

- Cancer
- Covid19

## Interventions

- **DRUG:** COVID-19 vaccine

## Key facts

- **NCT ID:** NCT04910295
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-26
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-12-31
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910295, "Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04910295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*